Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina
- 1 July 2008
- journal article
- other
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 27 (7), 660-661
- https://doi.org/10.1097/inf.0b013e3181691753
Abstract
Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommendations but did not receive palivizumab; 26% required hospitalization for respiratory syncytial virus infection. Siblings and bronchopulmonary dysplasia were associated with higher hospitalization. For high-risk patients, one averted hospitalization was associated with costs of U.S. dollars (USD)13, 198 [number needed to treat (NNT): 4.5].Keywords
This publication has 8 references indexed in Scilit:
- Relevance of Cost-effectiveness Analysis to Clinicians and Policy MakersJAMA, 2007
- Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk ChildrenPharmacoEconomics, 2007
- The Impact of Infection with Human Metapneumovirus and Other Respiratory Viruses in Young Infants and Children at High Risk for Severe Pulmonary DiseaseThe Journal of Infectious Diseases, 2006
- Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus InfectionsPEDIATRICS, 2003
- Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract diseaseThe Journal of Pediatrics, 2003
- Economic Analyses of Respiratory Syncytial Virus Immunoprophylaxis in High-Risk InfantsArchives of Pediatrics & Adolescent Medicine, 2002
- Respiratory syncytial virus prophylaxis: cost-effective analysis in ArgentinaThe Pediatric Infectious Disease Journal, 2002
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPEDIATRICS, 1998